VirusExpress® 293 AAV Production Platform
Source: MilliporeSigma
You’re developing lifesaving gene therapies and need to manufacture AAV vector as quickly as possible. But scale-up and regulatory hurdles make the path to the clinic slow and labor intensive. We’re here to help.
The VirusExpress® 293 AAV Production Platform offers a transfection-based solution using a suspension-adapted cell line, which is GMP banked and characterized, chemically defined medium, and a process with proven performance at clinically relevant scale.
Draw on our 30+ years of viral vector manufacturing experience and a platform that can dramatically reduce your process development and scale-up time to speed your therapy to patients.
Find out how you can get on the fast track through production.
MilliporeSigma
This website uses cookies to ensure you get the best experience on our website. Learn more